Mimedx (MDXG) Other Non-Current Liabilities (2011 - 2026)
Mimedx recorded quarterly Other Non-Current Liabilities of $5.1 million in Q1 2026, down 5.14% quarter-over-quarter from $5.4 million in Q4 2025, and down 31.98% year-over-year from $7.5 million in Q1 2025.
Mimedx's Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 31.98% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 31.98% YoY), while the FY2025 annual figure was $5.4 million, down 27.24% from the prior year.
- Other Non-Current Liabilities came in at $5.1 million for Q1 2026 at Mimedx, down from $5.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $7.5 million in Q1 2025 to a low of $2.2 million in Q4 2023.
- A 5-year average of $4.8 million and a median of $4.8 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities tumbled 53.43% in 2023 and soared 232.12% in 2024, its largest moves.
- Mimedx's Other Non-Current Liabilities stood at $4.8 million in 2022, then sank by 53.43% to $2.2 million in 2023, then jumped by 232.12% to $7.4 million in 2024, then retreated by 27.24% to $5.4 million in 2025, then declined by 5.14% to $5.1 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.1 million, $5.4 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.10 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 5.52 Mn |
| Jun 30, 2025 | 6.98 Mn |
| Mar 31, 2025 | 7.49 Mn |
| Dec 31, 2024 | 7.38 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 5.28 Mn |
| Dec 31, 2023 | 2.22 Mn |
| Sep 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 4.03 Mn |
| Dec 31, 2022 | 4.77 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 4.28 Mn |
| Mar 31, 2022 | 4.55 Mn |
| Dec 31, 2021 | 4.87 Mn |
| Sep 30, 2021 | 4.08 Mn |
| Jun 30, 2021 | 3.31 Mn |
| Mar 31, 2021 | 3.62 Mn |
| Dec 31, 2020 | 3.76 Mn |
| Sep 30, 2020 | 4.42 Mn |
| Jun 30, 2020 | 2.92 Mn |
| Mar 31, 2020 | 3.23 Mn |
| Dec 31, 2019 | 3.54 Mn |
| Sep 30, 2019 | 4.15 Mn |
| Jun 30, 2019 | 4.45 Mn |
| Mar 31, 2019 | 4.74 Mn |
| Dec 31, 2018 | 1.64 Mn |
| Dec 31, 2017 | 1.65 Mn |
| Jun 30, 2017 | 1.08 Mn |
| Mar 31, 2017 | 1.09 Mn |
| Dec 31, 2016 | 875,000.00 |
| Sep 30, 2016 | 832,000.00 |
| Jun 30, 2016 | 15.98 Mn |
| Mar 31, 2016 | 33.24 Mn |
| Sep 30, 2015 | 1.05 Mn |
| Jun 30, 2015 | 1.14 Mn |
| Mar 31, 2015 | 1.24 Mn |
| Dec 31, 2014 | 1.53 Mn |
| Sep 30, 2014 | 1.61 Mn |
| Jun 30, 2014 | 1.62 Mn |
| Mar 31, 2014 | 1.52 Mn |
| Dec 31, 2013 | 1.52 Mn |
| Sep 30, 2013 | 1.43 Mn |
| Jun 30, 2013 | 1.25 Mn |
| Mar 31, 2013 | 288,438.00 |
| Dec 31, 2012 | 353,333.00 |
| Sep 30, 2012 | 311,085.00 |
| Jun 30, 2012 | 320,055.00 |
| Mar 31, 2012 | 322,464.00 |
| Dec 31, 2011 | 312,493.00 |
| Sep 30, 2011 | 48,862.00 |
| Jun 30, 2011 | 30,197.00 |